Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review

Miriana d'Alessandro1, Edoardo Conticini2, Laura Bergantini1

  • 1Respiratory Diseases Unit, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, 53100 Siena, Italy.

Life (Basel, Switzerland)
|February 25, 2022
PubMed
Abstract

Insights

Neutrophil extracellular traps (NETs) are involved in ANCA-associated vasculitis with interstitial lung disease (AAV-ILD). Inhibiting NETs may offer a new therapeutic strategy for this severe condition, though more research is needed.

Area of Science:

  • Immunology
  • Pulmonology
  • Rheumatology

Background:

  • Neutrophil extracellular traps (NETs) formation is implicated in diseases like ANCA-associated vasculitis (AAV) and pulmonary fibrosis (PF).
  • Lung involvement, specifically interstitial lung diseases (ILDs), is common in AAV, particularly with MPO-ANCA positivity, and indicates a poor prognosis.
  • The interplay between neutrophils, ANCA, and NETs is crucial in the development of PF in AAV.

Purpose of the Study:

  • To review the literature on the role of NETs in lung fibrogenesis within the context of AAV-associated ILD.
  • To explore the potential of NETs as a theranostic marker for AAV-ILD.

Main Methods:

  • Scoping review methodology was employed.
  • Descriptive thematic analysis was used to understand the pathogenic role of NETs in AAV and pulmonary fibrosis.
  • The role of NETs as a theranostic marker was also investigated.

Main Results:

  • NETs play a role in the pathogenesis of AAV and ILD, though mechanisms remain unclear.
  • Inhibition of NET release has shown reduced disease severity in inflammatory models, suggesting NETs as therapeutic targets.
  • Optimal AAV-ILD management may require B-cell targeted therapy combined with NET inhibition, despite limited clinical data.

Conclusions:

  • Traditional immunosuppressants like Rituximab may have limited efficacy in AAV-ILD.
  • No patients with definite ILD have been enrolled in clinical trials for NET-targeted therapies.
  • Further research is needed to establish the scientific basis for NET inhibition as a treatment to reduce severity and mortality in AAV-ILD.

Related Concept Videos